GlassScriptPhysician profile
Michelle Lemaster
NPI 1396394920
$6,928.33
in general payments reported to CMS, 2019-2025
25 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $189 · 2023: $1,011 · 2024: $2,114 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,739.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,489.73 | 2023-2025 | |
| Axsome Therapeutics, INC. | $1,093.13 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $822.45 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $516.86 | 2024-2025 | Qelbree |
| Neos Therapeutics, LP | $412.21 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Janssen Pharmaceuticals, INC | $272.00 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $260.20 | 2023-2025 | Caplyta |
| Lundbeck LLC | $245.40 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $228.26 | 2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $208.27 | 2022-2025 | Ingrezza |
| Corium, LLC | $202.75 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $199.90 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Biogen, INC. | $184.72 | 2025 | Zurzuvae |
| Tris Pharma INC | $100.48 | 2023-2025 | Dyanavel Xr |
| Baxter Healthcare | $97.54 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $92.58 | 2025 | Jornay Pm |
| Tempus Ai, INC | $92.36 | 2024 | |
| Ironshore Pharmaceuticals INC. | $87.77 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $71.90 | 2024-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $59.84 | 2025 | Trintellix |
| Alkermes, INC. | $53.28 | 2024-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $50.31 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $46.41 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $25.49 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lemaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.